Navigation Links
GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
Date:9/8/2009

NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Anders Boegh Jensen to its Scientific Advisory Board (SAB).

Dr. Boegh Jensen will contribute his considerable expertise in biotechnology and molecular biology to GENova's business of identifying, evaluating and developing pioneering research drugs. His expertise is acknowledged by companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

Aaron Whiteman, CEO of GENova, says, "We are delighted to have Mr. Boegh Jensen join the SAB. His credentials and experience in the biotech field will be an asset to GENova as we continue to identify promising cancer-fighting drug patents."

Anders Boegh Jensen, Ph.D.

Anders Boegh Jensen is a biochemist who specializes in biotechnology, genetics and molecular biology. He is currently the Director at Poalis, a plant-based biotechnology company, and serves as an Industrial Representative Board Member at the Danish Society for Biochemistry and Molecular Biology. Dr. Boegh Jensen is also frequently published in leading industry journals such as "Cell". His previous position was Associate Professor at the Institute of Molecular Biology at the University of Copenhagen where he helped modernize biology education and developed advanced Ph.D. courses.

Anders Boegh Jensen's academic credentials include: completion of a Master's thesis at the Institute of Molecular Biology, University of Copenhagen in 1989; a one-year research term at the Carlsberg Research Laboratory; and being awarded a four-year European Union BRIDGE mobility fellowship for his post-graduate research training at the Dept. of Plant Molecular Genetics, CID, CSIC, Barcelona, Spain. He completed his Ph.D thesis in Molecular Biology and Genetics in 1994.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genova files patent for new prostate cancer treatment
2. GENova names Dr. John Savin as Vice President
3. GENova names Aaron Whiteman as CEO
4. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
5. KV Pharmaceutical Appoints Interim Chief Financial Officer
6. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
7. Mindray DS USA Appoints Michael Thompson Vice President of U.S. Ultrasound Sales
8. XLHealth Appoints New Controller to Lead Financial Compliance, Accounting Initiatives
9. IMIA Interpreter Association Appoints Brazil Representative
10. HCA Appoints Dr. Richard Tayrien Chief Health Information Officer
11. SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... California (PRWEB) , ... February 17, 2017 , ... ... info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn ... fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory from the ... to easily connect elderly veterans of America's armed forces to a range of ... conveys material on this year's increase in the Veterans Pension with Aid & ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... , ... February 17, 2017 ... ... Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 ... the critical reimbursement questions manufacturers should be asking before selecting an FDA ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, ... is expected to grow at a CAGR of 9.4% from 2017-2022 ... grow at a CAGR of 9.5% from 2017 to 2027. The ... ... will benefit you Read on to discover how you can ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets has ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology: